Brief: Akari Therapeutics Provides Updates On Development Of Nomacopan In Pediatric And Adult HSCT-TMA
13/07/2023 13:58
July 13 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS PROVIDES UPDATES ON DEVELOPMENT OF
NOMACOPAN
IN PEDIATRIC AND ADULT HSCT-TMA
* AKARI THERAPEUTICS - ON TRACK FOR START OF ENROLLMENT BY
END OF
2023 IN REGISTRATIONAL PHASE 3 STUDY OF NOMACOPAN IN PEDIATRIC
HSCT-TMA
* AKARI THERAPEUTICS-MOVING FORWARD INTO PHASE 3
DOUBLE-BLIND
PLACEBO-CONTROLLED CLINICAL TRIAL OF NOMACOPAN IN ADULT
HSCT-TMA, TO BEGIN ENROLLMENT IN 2024
Source text for Eikon: ID:nGNEb0hHL3
Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics